Enanta Pharmaceuticals Inc (ENTA)vsVertex Pharmaceuticals Inc (VRTX)
ENTA
Enanta Pharmaceuticals Inc
$13.00
+4.42%
HEALTHCARE · Cap: $371.62M
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 17553% more annual revenue ($12.22B vs $69.21M). VRTX leads profitability with a 35.5% profit margin vs -89.6%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
ENTA
Avoid27
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.0%
Fair Value
$24.14
Current Price
$13.00
$11.14 discount
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
15.0% revenue growth
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -53.2% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ENTA
The strongest argument for ENTA centers on Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ENTA
The primary concerns for ENTA are Market Cap, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ENTA profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
ENTA carries more volatility with a beta of 0.97 — expect wider price swings.
ENTA is growing revenue faster at 15.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 27/100), backed by strong 35.5% margins. ENTA offers better value entry with a 41.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enanta Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?